ClinicalTrials.gg
CompletedNCT00090103Updated Feb 28, 2017Results posted

Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment

A Phase 3 interventional study of dutasteride 0.5mg once daily for 4 years and tamsulosin 0.4mg once daily for 4 years in Prostatic Hyperplasia, sponsored by GlaxoSmithKline. Completed at 504 sites in 36 countries. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2017-02-28.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,844
Allocation
Randomized
Ages
50 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing dutasteride in Prostatic Hyperplasia — 1 open to participants now, 1 under way, none of them phase 3. Dutasteride · Prostatic Hyperplasia.

Enrollment
Largest of 27
4,844 · median 44
Started
2003
with 2 others
Phase 3
4 of 27
none open now
Registered
2nd of 27
by date
Lead sponsor
15 of 27
GlaxoSmithKline

Among the 27 studies testing dutasteride in Prostatic Hyperplasia, this one has the largest enrollment, is one of 3 that started in 2003, is one of 4 in phase 3, and was the 2nd registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

1 of the 27 studies testing dutasteride in Prostatic Hyperplasia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About dutasteride

Dutasteride: first FDA approval 2001 (AVODART). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 50 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing dutasteride in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

This study will investigate the efficacy and safety of treatment with dutasteride and tamsulosin, administered once daily for 4 years, alone and in combination, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic Benign Prostatic Hyperplasia (BPH). Study visits are every 3 months for up to 4 years (18 clinic visits). Transrectal ultrasound (TRUS) is done annually.

Read the detailed description

A randomised, double-blind, parallel group study to investigate the efficacy and safety of treatment with Dutasteride (0.5 mg) and Tamsulosin (0.4 mg), administered once daily for 4 years, alone and in combination, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic benign prostatic hyperplasia.

03

Conditions studied

  • Prostatic Hyperplasia

Browse trials for

Keywords

  • Combination Therapy
  • dutasteride
  • BPH
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A subject will be considered eligible for inclusion in this study only if all of the following criteria apply:
  • males, aged ≥50 years
  • clinical diagnosis of BPH by medical history and physical examination, including a digital rectal examination (DRE)
  • International Prostate Symptom Score (IPSS) ≥12 points at Screening
  • prostate volume ≥30 cc by transrectal ultrasonography; (TRUS)
  • total serum Prostate Specific Antigen (PSA) ≥1.5ng/mL at Screening
  • maximum flow rate (Qmax) >5 mL/sec and ≤15 mL/sec and minimum voided volume of ≥125 mL at Screening (based on two voids)
  • willing and able to give written and comply with study procedures
  • fluent and literate in local language with the ability to read, comprehend and record information on the IPSS, BII and Patient Perception of Study Medication
  • able to swallow and retain oral medication
  • willing and able to participate in the study for the full 4 years.

Exclusion criteria

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

  • total serum PSA >10.0ng/mL at Screening
  • history or evidence of prostate cancer (e.g. positive or ultrasound, suspicious DRE). Patients with suspicious ultrasound or DRE who have had a negative biopsy within the preceding 6 months and stable PSA are eligible for the study.

Note: If total serum PSA is >4ng/mL and unless PSA value has been stable for at least the past 2 years, the investigator should make every appropriate effort to exclude the possibility of prostate cancer, e.g. further DRE, review TRUS taken within previous month, consider 8-12 core prostate biopsy in accordance with routine clinical practice.

  • previous prostatic surgery (including TURP, balloon dilatation, thermotherapy and stent replacement) or other invasive procedures to treat BPH.
  • history of flexible/rigid cystoscopy or other instrumentation of the urethra within 7 days prior to the Screening Visit. Routine catheterisation is acceptable with no time restriction.
  • history of AUR within 3 months prior to Screening Visit.
  • post-void residual volume >250mL (suprapubic ultrasound) at Screening.
  • any causes other than BPH, which may in the judgement of the investigator, result in urinary symptoms or changes in flow rate (e.g. neurogenic bladder, bladder neck contracture, urethral stricture, bladder , acute or chronic prostatitis, or acute or chronic urinary tract infections).
  • history of breast cancer or clinical breast examination finding of unclear origin or suggestive of malignancy.
  • use of any 5-alpha-reductase inhibitor (e.g. Proscar®, Propecia®, Avodart®), any drugs with antiandrogenic properties (e.g. spironolactone, flutamide, bicalutamide, cimetidine, ketoconazole, metronidazole, progestational agents), or other drugs which affect prostate volume, within past 6 months of the Screening Visit and throughout the study (other than as study medication).
  • concurrent use of anabolic steroids
  • use of phytotherapy for BPH within 2 weeks of Screening Visit and/or predicted to need phytotherapy during the study.
  • use of any alpha-adrenoreceptor blockers (i.e. indoramin, prazosin, terazosin, tamsulosin, alfuzosin and doxazosin) within 2 weeks of Screening Visit and/or predicted to need any alpha blockers other than tamsulosin during the study.

Note: the purpose of this criteria is to be able to standardise baseline symptom severity for all enrolled patients prior to randomisation and not to specifically exclude current alpha-adrenoreceptor blocker users from participation in the study.

  • use of any alpha-adrenoreceptor agonists (e.g. pseudoephedrine, phenylephrine, ephedrine) or anticholinergics (e.g. oxybutynin, propantheline) or cholinergics (e.g. bethanecol chloride) within 48 hours prior to all uroflowmetry assessments.
  • to any alpha-/beta- adrenoreceptor blocker or 5-alpha-reductase inhibitor, or other chemically-related drugs.
  • concurrent use of drugs known or thought to have an interaction with tamsulosin, e.g. cimetidine and warfarin.
  • history of hepatic impairment or abnormal liver function tests at Screening defined as (ALT), aspartate aminotranferase (AST), and/or alkaline phosphatase >2 times the , or total >1.5 times the upper limit of normal (unless associated with predominantly indirect bilirubin elevation or Gilbert's syndrome).
  • history of renal insufficiency, or serum creatinine >1.5 times the upper limit of normal or serum creatinine ≥1.5 mg/dL at Screening.
  • prior history of malignancies other than basal cell carcinoma or squamous cell carcinoma of the skin within the past 5 years. Subjects with a prior malignancy who have had no evidence of disease for at least the past 5 years are eligible.
  • history of any illness that in the opinion of the investigator might confound the results of the study or poses additional risk to the patient.
  • any unstable, serious co-existing medical condition(s) including, but not limited to, myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within 6 months prior to Screening visit; uncontrolled diabetes or peptic ulcer disease which is uncontrolled by medical management.
  • history of postural hypotension, dizziness, vertigo or any other signs and symptoms of orthostasis, which in the opinion of the investigator could be exacerbated by tamsulosin and result in putting the subject at risk of injury.
  • history of unsuccessful treatment with tamsulosin or 'first dose' hypotensive episode on initiation of alpha-1-adrenoreceptor antagonist therapy.
  • history of unsuccessful treatment with finasteride or dutasteride
  • history or current evidence of drug or alcohol abuse within the previous 12 months.
  • participation in any or marketed drug trial within 30 days (or 5 half-lives whichever is the longer) preceding the Screening Visit and/or during the course of this study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
4,844 participants (actual)

Study arms

  • Active comparator
    dutasteride

    dutasteride 0.5mg once daily

    Drug: dutasteride 0.5mg once daily for 4 years

  • Experimental
    Combo

    Combination of dutasteride (0.5mg) and tamsulosin (0.4mg), once daily

    Drug: dutasteride 0.5mg once daily for 4 years · Drug: tamsulosin 0.4mg once daily for 4 years

  • Active comparator
    tamsulosin

    tamsulosin 0.4mg once daily

    Drug: tamsulosin 0.4mg once daily for 4 years

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Events of Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery at the Indicated Time Periods.

    A participant was considered to have AUR when he was unable to urinate and required bladder catheterization. BPH is also known as an enlarged prostate. When symptoms of BPH become bothersome, surgery may be required. When events of AUR and BPH-related surgery were participant-reported or identified, they were recorded in the participants' clinic record.

    Time frame: Years 1, 2, 3, and 4

  2. Number of Participants With AUR or BPH-related Surgery

    A participant was considered to have AUR when he was unable to urinate and required bladder catheterization. BPH is also known as an enlarged prostate. When symptoms of BPH become bothersome, surgery may be required. When events of AUR and BPH-related surgery were participant reported or identified, they were recorded in the participants' clinic record.

    Time frame: Baseline (Day 1) through Year 4

Secondary outcomes

  1. Number of Events of First BPH Clinical Progression at Years 1, 2, 3 and 4

    The time when the first symptom/event of BPH clinical progression has occurred (i.e. AUR, incontinence) was measured. Summaries are based on the first occuring event after treatment start. The time period is from treatment start to each participant's last treatment visit. The Year 4 events include all those that occur during the fourth year and beyond.

    Time frame: Years 1, 2, 3, and 4

  2. The Number of Participants With Each of the Five Components of BPH Clinical Progression

    The five components measured were symptom deterioration, BPH-related AUR, BPH-related incontinence, recurrent BPH-related Urinary Tract Infection (UTI), and BPH-related renal insufficiency.

    Time frame: Baseline (Day 1) to Year 4

  3. Number of Events of Symptom Deterioration at the Indicated Time Periods

    The number of participants (par.) with symptom deterioration of International Prostate Symptom Score (IPSS) ≥4 points on two consecutive visits post-baseline are presented. Data are based on the first occurrence of an event after treatment start. The year-4 events include all that occured during the 4th year and beyond. The IPSS is a 7-item questionnaire measuring the level of urinary symptoms reported as the total score. Each question has a 6-point response scale (0=none/not at all to 5=almost always), with a total score ranging from 0-35: mild (0-7), moderate (8-19), or severe (20-35).

    Time frame: Years 1, 2, 3, and 4 (from treatment start until each participant's last treatment-phase visit)

  4. Number of Participants With an Event of Post-baseline BPH-related Macroscopic Hematuria

    A participant was considered to have macroscopic hematuria when there was presence of blood in the urine. The event of macroscopic hematuria was either participant-reported or identified by the investigator during a clinic visit. Overall Crude Rate is the number of participants from the total number analyzed that experience experienced an incident of post-baseline BPH or Non-BPH related macroscopic hematuria. Participants may appear in both categories.

    Time frame: Baseline (Day 1) through Year 4

  5. Number of Participants With an Event of Post-baseline BPH-related Hematospermia

    A participant was considered to have hematospermia when there was presence of blood in the semen. Hematospermia can occur from prostatitis (prostate infection), from cancer, or after a prostate biopsy. The event of hematospermia was either participant-reported or identified by the investigator during a clinic visit. Overall Crude Rate is the number of participants from the total number analyzed that experience experienced an incident of post-baseline BPH or Non-BPH related hematospermia. Participants may appear in both categories.

    Time frame: Baseline (Day 1) through Year 4

  6. Adjusted Mean Change From Baseline in International Prostate Symptom Score (IPSS) at Months 12, 24, 36, and 48

    The IPSS is a 7-item questionnaire that measures urinary symptoms. It measures the level of urinary symptoms (including incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia) reported as the total IPSS score. Each of the 7 questions has a 6-point response scale (0=none/not at all to 5=almost always) with a total score that can range from 0-35: mild (0-7), moderate (8-19), or severe (20-35). Estimates are based on adjusted (least squares) means from the general linear model: change from baseline IPSS = Treatment + Cluster + Baseline IPSS.

    Time frame: Baseline and Months 12, 24, 36, and 48

  7. Adjusted Mean Change From Baseline in Urinary Flow Rate (Qmax) at Months 12, 24, 36, and 48

    Peak maximum urinary flow (Qmax) of urinary flow using a Medtronic (formerly Dantec) Uroflow Meter (Urodyn 1000 or Duet models) with a Thompson filter was measured. Estimates are based on adjusted (least squares) means from the general linear model: Change from baseline Qmax = treatment + cluster + baseline Qmax.

    Time frame: Baseline and Months 12, 24, 36, and 48

  8. Adjusted Mean Percent Change From Baseline in Prostate Volume at Months 12, 24, 36, and 48

    Prostate volume measurements were conducted annually using Transurethral ultrasound (TRUS). The anteroposterior, cephalocaudal, and transverse diameters of the prostate obtained by TRUS calculate the total prostate volume centimeters (cc). Percent change from baseline = \[(post-baseline - baseline)/baseline value\] x 100. Estimates were based on the adjusted (least squares) means from the general linear model: log(post-baseline/baseline value) + treatment + cluster + log(baseline value) and are reported as percent change from baseline.

    Time frame: Baseline and Months 12, 24, 36, and 48

  9. Adjusted Mean Change From Baseline in Transition Zone (Portion of the Prostate That Surrounds the Proximal Urethra) Volume at Months 12, 24, 36, and 48

    Prostate volume (PV) measurements were conducted annually using Transurethral ultrasound (TRUS). The anteroposterior, cephalocaudal, and transverse diameters of the prostate obtained by TRUS calculate the total PV in centimeters (cc). Results are for the transition zone measurements of the prostate in a small subset of participants. Percent change from baseline (BL) = \[(post-BL - BL)/BL value\] x 100. Estimates are based on the adjusted (least squares) means for the general linear model: log(post-BL/BL value) = treatment + cluster + log(BL value) and are reported as percent change from BL.

    Time frame: Baseline and Months 12, 24, 36, and 48

  10. Number of Unscheduled Visits to GP/Urologist Regarding AUR Symptoms Since the Last Study Visit

    At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with an episode of AUR. Responses to the following question were recorded: "Has the participant needed to make any unscheduled visits to his general practitioner (GP)/Urologist regarding AUR symptoms since the last study visit?" If the answer to the question was "yes," the number of visits was recorded.

    Time frame: Every 3 months from Month 3 to Month 48

  11. Number of "Yes" Responses to the Question: "Would the Participant Have Paid a Visit to His GP/Urologist Regarding AUR Symptoms if the Study Visit Had Not Been Planned"?.

    At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with an episode of AUR. Responses to the following question were recorded: "Would the participant have paid a visit to his GP/Urologist regarding AUR symptoms if this study visit had not been planned?". If the answer to the question was "yes," the number of Yes responses was recorded.

    Time frame: Every 3 months from Month 3 to Month 48

  12. Number of Visits to GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit

    At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with BPH-related surgery. Responses to the following question were recorded: "Has the participant needed to visit his general practitioner (GP)/Urologist regarding BPH-related surgery since the last study visit?". If the answer to the question was "yes," the number of visits was recorded.

    Time frame: Every 3 months from Month 3 to Month 48

  13. Number of "Yes" Responses to the Question: "Would the Participant Have Paid a Visit to His GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit?"

    At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with BPH-related surgery. Responses to the following question were recorded: "Would the participant have paid a visit to his general practitioner (GP)/Urologist regarding BPH-related surgery since the last study visit?". If the answer to the question was "yes," the number of Yes responses was recorded.

    Time frame: Every 3 months from Month 3 to Month 48

  14. Number of Unplanned Visits to GP/Urologist That Would Have Taken Place if a Scheduled Study Visit Had Not Been Planned (Including Visits Resulting From UTI, UI, Macroscopic Haematuria, Etc.)

    At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with unplanned visits to GP/Urologist. Responses to the following question were recorded: "Has the participant had any unplanned GP/Urologist (outpatient) visits that would have taken place if a scheduled study visit had not been planned (this can include visits resulting from UTI, UI macroscopic haematuria, etc?". If the answer to the question was "yes," the number of visits was recorded.

    Time frame: Every 3 months from Month 3 to Month 48

  15. Number of Unscheduled Visits to GP/Urologist (Outpatient) Planned, Not Relating to the Study (Including Visits Resulting From UTI, UI, Macroscopic Haematuria, Etc.)

    At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with unplanned visits to GP/Urologist. Responses to the following question were recorded: "Does the participant have any unscheduled GP/Urologist (outpatients) visits planned, not relating to the study (this can include visits resulting from UTI, UI, macroscopic haematuria, etc.?". If the answer to the question was "yes," the number of visits was recorded.

    Time frame: Every 3 months from Month 3 to Month 48

  16. Adjusted Mean Change From Baseline in BPH Impact Index (BII) at Months 12, 24, 36, and 48

    The BII is a 4-item questionnaire, score range of 0 (best) to 12 (worst) for questions 1-3, and 0 (best) to 13 (worst) for question 4, that assesses the overall impact of BPH on a participant's general sense of well being and measures aspects of physical discomfort, worry, and bother, all of which can be affected by BPH and its symptoms. BII score = sum of questions 1-4. Change from baseline = Post-Baseline Value. Estimates are based on the adjusted (least squares) means from the general linear model: change from baseline BII = treatment + cluster + baseline BII.

    Time frame: Baseline and Months 12, 24, 36, and 48

  17. Adjusted Mean Change From Baseline in BPH-Related Health Status (BHS) at Months 12, 24, 36, and 48

    The effect of study treatment on BHS was assessed by using three self-administered questionnaires: the International Prostate Symptom Score (IPSS), the BPH Impact Index (BII), and Patient Perception of Study Medication (PPSM). The BHS score was collected on the IPPS questionnaire and ranged from 0 (best) to 6 (worst). Percent change from baseline = \[(post-baseline - baseline)/baseline value\] x 100. Estimates were based on the adjusted (least squares) means from the general linear model: change from baseline BPH-related health status = treatment + cluster + baseline BPH-Related health status.

    Time frame: Baseline and Months 12, 24, 36, 48

  18. Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 1 (LOCF)

    This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Since you began taking the study medication, how has control of your urinary problems changed?".

    Time frame: Baseline and Months 12, 24, 36, and 48

  19. Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 2 (LOCF)

    This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "How satisfied are you with the effect of the study medication on control of your urinary problems?" Satisfact., satisfaction.

    Time frame: Baseline and Months 12, 24, 36, and 48

  20. Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 3 (LOCF)

    This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Since you began taking the study medication, how has the strength of your urinary stream changed?".

    Time frame: Baseline and Months 12, 24, 36, and 48

  21. Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 4 (LOCF)

    This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "How satisfied are you with the effect of the study medication on the strength of your urinary stream?". Satisfact., satisfaction.

    Time frame: Baseline and Months 12, 24, 36, and 48

  22. Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 5 (LOCF)

    This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Since you began taking the study medication, how has your pain prior to urinating changed?".

    Time frame: Baseline and Months 12, 24, 36, and 48

  23. Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 6 (LOCF)

    This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "How satisfied are you with the effect the study medication has on your pain prior to urinating?". Satisfact., satisfaction.

    Time frame: Baseline and Months 12, 24, 36, and 48

  24. Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 7 (LOCF)

    This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Since you began taking the study medication, how has your pain during urination changed?".

    Time frame: Baseline and Months 12, 24, 36, and 48

  25. Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 8 (LOCF)

    This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "How satisfied are you with the effect the study medication has on your pain during urination?". Satisfact., satisfaction.

    Time frame: Baseline and Months 12, 24, 36, and 48

  26. Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 9 (LOCF)

    This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Since you began taking the study medication, how has the way your urinary problems interfere with your ability to go about your usual activities changed?".

    Time frame: Baseline and Months 12, 24, 36, and 48

  27. Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 10 (LOCF)

    This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "How satisfied are you with the effect the study medication has on your ability to go about your usual activities without interference from your urinary problems?". Satisfact., satisfaction.

    Time frame: Baseline and Months 12, 24, 36, and 48

  28. Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 11 (LOCF)

    This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Overall, how satisfied are you with the study medication and it's effect on your urinary problems?". Satisfact., satisfaction.

    Time frame: Baseline and Months 12, 24, 36, and 48

  29. Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 12 (LOCF)

    This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Would you ask your doctor for the medication you received in this study?".

    Time frame: Baseline and Months 12, 24, 36, and 48

07

Results

Posted Mar 16, 2010

Participant flow

Four-Year Double-Blind Treatment Period
Participant flow — Four-Year Double-Blind Treatment Period
MilestoneDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Started161016231611
Completed11131093989
Not completed497530622
Withdrew: Adverse event211185210
Withdrew: Withdrawal by subject114160148
Withdrew: Lost to follow-up534858
Withdrew: Protocol violation292934
Withdrew: Lack of efficacy5371104
Withdrew: Participant relocated728
Withdrew: Site closed/sponsor termination774
Withdrew: Non-compliant/medication interruption647
Withdrew: Prostate surgery/turp/alt. therapy3719
Withdrew: Participant decision/withdrawn204
Withdrew: Acute urinary retention (aur)236
Withdrew: Prohibited medication228
Withdrew: Investigator departure200
Withdrew: Alcohol dependent100
Withdrew: Screen failure100
Withdrew: No improvement100
Withdrew: Bph/bph symptoms worse/urinary incont.105
Withdrew: Financial problems100
Withdrew: Loss of libido100
Withdrew: Angina pectoris020
Withdrew: Loss of contact010
Withdrew: Neoplasm of bladder/prostate011
Withdrew: Cardiologist/neurologist decision020
Withdrew: Renal insufficiency010
Withdrew: Back pain010
Withdrew: Scheduling issues010
Withdrew: Any appreciable improvement010
Withdrew: Investigator decision013
Withdrew: Enrollment error002
Withdrew: Urinary tract infection (uti)001
Withdrew: Prostate specific antigen rising010
16-Week Safety Follow-up Period
Participant flow — 16-Week Safety Follow-up Period
MilestoneDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Started159816151600
Completed122412051143
Not completed374410457
Withdrew: Adverse event343944
Withdrew: Withdrawal by subject185212229
Withdrew: Lost to follow-up10197111
Withdrew: Protocol violation181817
Withdrew: Site closed/sponsor termination854
Withdrew: Non-compliant/medication interruption864
Withdrew: Loss of contact402
Withdrew: Disease progression/treatment failure311
Withdrew: Participant relocated231
Withdrew: Participant decision/withdrawn212
Withdrew: Prohibited medication235
Withdrew: Alcohol dependent101
Withdrew: Prostate surgery/turp/alt. therapy1513
Withdrew: Loss of libido100
Withdrew: Enrollment error102
Withdrew: Neoplasm of bladder/prostate cancer136
Withdrew: Death101
Withdrew: Gyneomastia100
Withdrew: Acute urinary retention (aur)054
Withdrew: Bph/bph symptoms worse/urinary incont.023
Withdrew: Angina pectoris010
Withdrew: Back pain010
Withdrew: Scheduling issues024
Withdrew: Investigator/sponsor decision023
Withdrew: Depression010
Withdrew: Diabetes uncontrolled010
Withdrew: Jailed010
Withdrew: Other010

Outcome measures

PrimaryNumber of Events of Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery at the Indicated Time Periods.

A participant was considered to have AUR when he was unable to urinate and required bladder catheterization. BPH is also known as an enlarged prostate. When symptoms of BPH become bothersome, surgery may be required. When events of AUR and BPH-related surgery were participant-reported or identified, they were recorded in the participants' clinic record.

Time frame:
Years 1, 2, 3, and 4
Reported as:
Number · events
Number of Events of Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery at the Indicated Time Periods.
eventsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Year 1, n=1610, 1623, 1611292740
Year 2, n=1457, 1484, 1464142262
Year 3, n=1347, 1365, 1307151644
Year 4, n=1274, 1277, 117691945
Statistical analysis
  • Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg vs Dutasteride 0.5 mg · Log Rank · p = 0.18 (Log-rank test with stratification by cluster.) · Relative risk estimate: 0.80 · 95% CI 0.58 to 1.11
  • Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg vs Tamsulosin 0.4 mg · Log Rank · p = <0.001 (Log-rank test with stratification by cluster.) · Relative risk estimate: 0.34 · 95% CI 0.26 to 0.45
SecondaryNumber of Events of First BPH Clinical Progression at Years 1, 2, 3 and 4

The time when the first symptom/event of BPH clinical progression has occurred (i.e. AUR, incontinence) was measured. Summaries are based on the first occuring event after treatment start. The time period is from treatment start to each participant's last treatment visit. The Year 4 events include all those that occur during the fourth year and beyond.

Time frame:
Years 1, 2, 3, and 4
Reported as:
Number · events
Number of Events of First BPH Clinical Progression at Years 1, 2, 3 and 4
eventsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Year 1, n=1610, 1623, 1611126184171
Year 2, n= 1264, 1240, 1262315478
Year 3, n=1135, 1082, 1048302967
Year 4, n= 1047, 959, 880162231
PrimaryNumber of Participants With AUR or BPH-related Surgery

A participant was considered to have AUR when he was unable to urinate and required bladder catheterization. BPH is also known as an enlarged prostate. When symptoms of BPH become bothersome, surgery may be required. When events of AUR and BPH-related surgery were participant reported or identified, they were recorded in the participants' clinic record.

Time frame:
Baseline (Day 1) through Year 4
Reported as:
Number · participants
Number of Participants With AUR or BPH-related Surgery
participantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
AUR3544109
BPH-related surgery324082
Statistical analysis
  • Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg vs Dutasteride 0.5 mg · Log Rank · p = 0.18 (Log rank test with stratification by cluster.)
  • Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg vs Tamsulosin 0.4 mg · Log Rank · p = <0.001 (Log rank test with stratification by cluster.)
SecondaryThe Number of Participants With Each of the Five Components of BPH Clinical Progression

The five components measured were symptom deterioration, BPH-related AUR, BPH-related incontinence, recurrent BPH-related Urinary Tract Infection (UTI), and BPH-related renal insufficiency.

Time frame:
Baseline (Day 1) to Year 4
Reported as:
Number · participants
The Number of Participants With Each of the Five Components of BPH Clinical Progression
participantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Symptom deterioration132203221
BPH-related AUR223164
BPH-related incontinence464956
Recurrent BPH-related UTI253
BPH-related renal insufficiency125
SecondaryNumber of Events of Symptom Deterioration at the Indicated Time Periods

The number of participants (par.) with symptom deterioration of International Prostate Symptom Score (IPSS) ≥4 points on two consecutive visits post-baseline are presented. Data are based on the first occurrence of an event after treatment start. The year-4 events include all that occured during the 4th year and beyond. The IPSS is a 7-item questionnaire measuring the level of urinary symptoms reported as the total score. Each question has a 6-point response scale (0=none/not at all to 5=almost always), with a total score ranging from 0-35: mild (0-7), moderate (8-19), or severe (20-35).

Time frame:
Years 1, 2, 3, and 4 (from treatment start until each participant's last treatment-phase visit)
Reported as:
Number · events
Number of Events of Symptom Deterioration at the Indicated Time Periods
eventsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Year 1, n=1610, 1623, 161191138119
Year 2, n=1286, 1278, 1296233849
Year 3, n=1158, 1132, 1088142342
Year 4, n=1083, 1001, 926111319
Statistical analysis
  • Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg vs Dutasteride 0.5 mg · Log Rank · p = <0.001 · Relative risk estimate: 0.65 · 95% CI 0.52 to 0.80Log-rank test with stratification by cluster.
  • Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg vs Tamsulosin 0.4 mg · Log Rank · p = <0.001 · Relative risk estimate: 0.59 · 95% CI 0.48 to 0.72
SecondaryNumber of Participants With an Event of Post-baseline BPH-related Macroscopic Hematuria

A participant was considered to have macroscopic hematuria when there was presence of blood in the urine. The event of macroscopic hematuria was either participant-reported or identified by the investigator during a clinic visit. Overall Crude Rate is the number of participants from the total number analyzed that experience experienced an incident of post-baseline BPH or Non-BPH related macroscopic hematuria. Participants may appear in both categories.

Time frame:
Baseline (Day 1) through Year 4
Reported as:
Number · participants
Number of Participants With an Event of Post-baseline BPH-related Macroscopic Hematuria
participantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Overall crude rate537081
Non-BPH-related Crude Rate152825
BPH-Related Crude Rate404556
Statistical analysis
  • Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg vs Dutasteride 0.5 mg · Log Rank · p = 0.65Mantel-Haenszel test with stratification by cluster.
  • Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg vs Tamsulosin 0.4 mg · Log Rank · p = 0.10Mantel-Hanenszel test with stratification by cluster.
SecondaryNumber of Participants With an Event of Post-baseline BPH-related Hematospermia

A participant was considered to have hematospermia when there was presence of blood in the semen. Hematospermia can occur from prostatitis (prostate infection), from cancer, or after a prostate biopsy. The event of hematospermia was either participant-reported or identified by the investigator during a clinic visit. Overall Crude Rate is the number of participants from the total number analyzed that experience experienced an incident of post-baseline BPH or Non-BPH related hematospermia. Participants may appear in both categories.

Time frame:
Baseline (Day 1) through Year 4
Reported as:
Number · participants
Number of Participants With an Event of Post-baseline BPH-related Hematospermia
participantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Overall Crude Rate181920
Non-BPH-related Crude Rate239
BPH-related Crude Rate171711
Statistical analysis
  • Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg vs Dutasteride 0.5 mg · Log Rank · p = 0.95Mantel-Haenszel test with stratification by cluster.
  • Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg vs Tamsulosin 0.4 mg · Log Rank · p = 0.24Mantel-Haenszel test with stratification by cluster.
SecondaryAdjusted Mean Change From Baseline in International Prostate Symptom Score (IPSS) at Months 12, 24, 36, and 48

The IPSS is a 7-item questionnaire that measures urinary symptoms. It measures the level of urinary symptoms (including incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia) reported as the total IPSS score. Each of the 7 questions has a 6-point response scale (0=none/not at all to 5=almost always) with a total score that can range from 0-35: mild (0-7), moderate (8-19), or severe (20-35). Estimates are based on adjusted (least squares) means from the general linear model: change from baseline IPSS = Treatment + Cluster + Baseline IPSS.

Time frame:
Baseline and Months 12, 24, 36, and 48
Reported as:
Least squares mean · points on a scale
Adjusted Mean Change From Baseline in International Prostate Symptom Score (IPSS) at Months 12, 24, 36, and 48
points on a scaleDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Month 12-5.6 ± 0.15-4.2 ± 0.15-4.5 ± 0.15
Month 24-6.2 ± 0.15-4.9 ± 0.15-4.3 ± 0.15
Month 36-6.3 ± 0.16-5.2 ± 0.16-4.0 ± 0.16
Month 48-6.3 ± 0.16-5.3 ± 0.16-3.8 ± 0.16
SecondaryAdjusted Mean Change From Baseline in Urinary Flow Rate (Qmax) at Months 12, 24, 36, and 48

Peak maximum urinary flow (Qmax) of urinary flow using a Medtronic (formerly Dantec) Uroflow Meter (Urodyn 1000 or Duet models) with a Thompson filter was measured. Estimates are based on adjusted (least squares) means from the general linear model: Change from baseline Qmax = treatment + cluster + baseline Qmax.

Time frame:
Baseline and Months 12, 24, 36, and 48
Reported as:
Least squares mean · milliliters (mL)/second (sec)
Adjusted Mean Change From Baseline in Urinary Flow Rate (Qmax) at Months 12, 24, 36, and 48
milliliters (mL)/second (sec)Dutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Month 12, n=1477, 1482, 15102.0 ± 0.121.5 ± 0.120.9 ± 0.12
Month 24, n= 1492, 1501, 15192.4 ± 0.121.9 ± 0.120.9 ± 0.12
Month 36, n= 1495, 1504, 15212.6 ± 0.121.9 ± 0.120.6 ± 0.12
Month 48, n= 1495, 1505, 15232.4 ± 0.132.0 ± 0.130.7 ± 0.13
SecondaryAdjusted Mean Percent Change From Baseline in Prostate Volume at Months 12, 24, 36, and 48

Prostate volume measurements were conducted annually using Transurethral ultrasound (TRUS). The anteroposterior, cephalocaudal, and transverse diameters of the prostate obtained by TRUS calculate the total prostate volume centimeters (cc). Percent change from baseline = \[(post-baseline - baseline)/baseline value\] x 100. Estimates were based on the adjusted (least squares) means from the general linear model: log(post-baseline/baseline value) + treatment + cluster + log(baseline value) and are reported as percent change from baseline.

Time frame:
Baseline and Months 12, 24, 36, and 48
Reported as:
Least squares mean · percent change
Adjusted Mean Percent Change From Baseline in Prostate Volume at Months 12, 24, 36, and 48
percent changeDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Month 12, n=1411, 1442, 1451-24.1 ± 0.60-25.2 ± 0.59-1.5 ± 0.77
Month 24, n= 1427, 1451, 1465-26.9 ± 0.62-28.0 ± 0.610.0 ± 0.84
Month 36, n= 1430, 1455, 1468-27.6 ± 0.68-28.8 ± 0.661.6 ± 0.94
Month 48, n= 1430, 1455, 1468-27.3 ± 0.66-28.0 ± 0.654.6 ± 0.94
SecondaryAdjusted Mean Change From Baseline in Transition Zone (Portion of the Prostate That Surrounds the Proximal Urethra) Volume at Months 12, 24, 36, and 48

Prostate volume (PV) measurements were conducted annually using Transurethral ultrasound (TRUS). The anteroposterior, cephalocaudal, and transverse diameters of the prostate obtained by TRUS calculate the total PV in centimeters (cc). Results are for the transition zone measurements of the prostate in a small subset of participants. Percent change from baseline (BL) = \[(post-BL - BL)/BL value\] x 100. Estimates are based on the adjusted (least squares) means for the general linear model: log(post-BL/BL value) = treatment + cluster + log(BL value) and are reported as percent change from BL.

Time frame:
Baseline and Months 12, 24, 36, and 48
Reported as:
Least squares mean · percent change
Adjusted Mean Change From Baseline in Transition Zone (Portion of the Prostate That Surrounds the Proximal Urethra) Volume at Months 12, 24, 36, and 48
percent changeDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Month 12, n= 150, 159, 160-17.2 ± 3.29-15.6 ± 3.395.6 ± 4.09
Month 24, n= 153, 164, 160-23.4 ± 5.63-22.8 ± 5.868.7 ± 8.22
Month 36, n= 155, 164, 162-20.9 ± 3.97-26.7 ± 3.9014.7 ± 5.89
Month 48, n= 155, 164, 163-17.9 ± 4.45-26.5 ± 4.2118.2 ± 6.54
SecondaryNumber of Unscheduled Visits to GP/Urologist Regarding AUR Symptoms Since the Last Study Visit

At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with an episode of AUR. Responses to the following question were recorded: "Has the participant needed to make any unscheduled visits to his general practitioner (GP)/Urologist regarding AUR symptoms since the last study visit?" If the answer to the question was "yes," the number of visits was recorded.

Time frame:
Every 3 months from Month 3 to Month 48
Reported as:
Number · visits
Number of Unscheduled Visits to GP/Urologist Regarding AUR Symptoms Since the Last Study Visit
visitsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Month 3, n=1550, 1581, 1565867
Month 6, n=1479, 1517, 1514243
Month 9, n=1439, 1465, 1477438
Month 12, n=1400, 1431, 1434339
Month 15, n=1343, 1386, 1380366
Month 18, n=1318, 1350, 13283410
Month 21, n=1281, 1326, 1287339
Month 24, n=1263, 1293, 1244227
Month 27, n=1233, 1262, 1206167
Month 30, n=1222, 1221, 1166328
Month 33, n=1202, 1199, 1128345
Month 36, n=1187, 1174, 1095215
Month 39, n=1160, 1144, 1055225
Month 42, n=1149, 1126, 1035328
Month 45, n=1129, 1110, 1009124
Month 48, n=1113, 1093, 990122
SecondaryNumber of "Yes" Responses to the Question: "Would the Participant Have Paid a Visit to His GP/Urologist Regarding AUR Symptoms if the Study Visit Had Not Been Planned"?.

At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with an episode of AUR. Responses to the following question were recorded: "Would the participant have paid a visit to his GP/Urologist regarding AUR symptoms if this study visit had not been planned?". If the answer to the question was "yes," the number of Yes responses was recorded.

Time frame:
Every 3 months from Month 3 to Month 48
Reported as:
Number · yes responses
Number of "Yes" Responses to the Question: "Would the Participant Have Paid a Visit to His GP/Urologist Regarding AUR Symptoms if the Study Visit Had Not Been Planned"?.
yes responsesDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Month 3, n=1550, 1581, 1564313229
Month 6, n=1479, 1516, 1513212626
Month 9, n=1439, 1465, 1477181418
Month 12, n=1400, 1431, 14348139
Month 15, n=1343, 1386, 138091512
Month 18, n=1318, 1350, 1328171319
Month 21, n=1281, 1326, 1287101517
Month 24, n=1263, 1293, 1244598
Month 27, n=1233, 1262, 12069118
Month 30, n=1222, 1221, 1166799
Month 33, n=1202, 1199, 112891011
Month 36, n=1187, 1174, 1095545
Month 39, n=1160, 1144, 1055796
Month 42, n=1149, 1126, 1035688
Month 45, n=1129, 1110, 1009785
Month 48, n=1113, 1093, 990295
SecondaryNumber of Visits to GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit

At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with BPH-related surgery. Responses to the following question were recorded: "Has the participant needed to visit his general practitioner (GP)/Urologist regarding BPH-related surgery since the last study visit?". If the answer to the question was "yes," the number of visits was recorded.

Time frame:
Every 3 months from Month 3 to Month 48
Reported as:
Number · visits
Number of Visits to GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit
visitsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Month 3, n=1550, 1581, 1564033
Month 6, n=1479, 1517, 1514212
Month 9, n=1439, 1465, 1477223
Month 12, n=1400, 1431, 1434127
Month 15, n=1343, 1386, 1380257
Month 18, n=1318, 1350, 1328404
Month 21, n=1281, 1326, 1287103
Month 24, n=1263, 1293, 1244203
Month 27, n=1233, 1262, 1206334
Month 30, n=1222, 1221, 1165011
Month 33, n=1202, 1199, 1128015
Month 36, n=1187, 1174, 1095221
Month 39, n=1160, 1144, 1055132
Month 42, n=1149, 1126, 1035125
Month 45, n=1129, 1110, 1009032
Month 48, n=1113, 1093, 990021
SecondaryNumber of "Yes" Responses to the Question: "Would the Participant Have Paid a Visit to His GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit?"

At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with BPH-related surgery. Responses to the following question were recorded: "Would the participant have paid a visit to his general practitioner (GP)/Urologist regarding BPH-related surgery since the last study visit?". If the answer to the question was "yes," the number of Yes responses was recorded.

Time frame:
Every 3 months from Month 3 to Month 48
Reported as:
Number · yes responses
Number of "Yes" Responses to the Question: "Would the Participant Have Paid a Visit to His GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit?"
yes responsesDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Month 3, n=1550, 1581, 1564163428
Month 6, n=1479, 1516, 1513202316
Month 9, n=1438, 1465, 1477121017
Month 12, n=1400, 1431, 14345106
Month 15, n=1343, 1386, 1380999
Month 18, n=1318, 1350, 1328131210
Month 21, n=1281, 1326, 12871098
Month 24, n=1263, 1293, 1244473
Month 27, n=1233, 1262, 1206995
Month 30, n=1222, 1221, 1166794
Month 33, n=1202, 1199, 1128578
Month 36, n=1187, 1174, 1095352
Month 39, n=1160, 1144, 1055785
Month 42, n=1149, 1126, 1034982
Month 45, n=1129, 1110, 1009685
Month 48, n=1113, 1093, 990131
SecondaryNumber of Unplanned Visits to GP/Urologist That Would Have Taken Place if a Scheduled Study Visit Had Not Been Planned (Including Visits Resulting From UTI, UI, Macroscopic Haematuria, Etc.)

At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with unplanned visits to GP/Urologist. Responses to the following question were recorded: "Has the participant had any unplanned GP/Urologist (outpatient) visits that would have taken place if a scheduled study visit had not been planned (this can include visits resulting from UTI, UI macroscopic haematuria, etc?". If the answer to the question was "yes," the number of visits was recorded.

Time frame:
Every 3 months from Month 3 to Month 48
Reported as:
Number · visits
Number of Unplanned Visits to GP/Urologist That Would Have Taken Place if a Scheduled Study Visit Had Not Been Planned (Including Visits Resulting From UTI, UI, Macroscopic Haematuria, Etc.)
visitsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Month 3, n=1550, 1581, 1564232526
Month 6, n=1479, 1517, 1514233422
Month 9, n=1439, 1465, 1477163522
Month 12, n=1400, 1431, 1434302934
Month 15, n=1343, 1386, 1380242227
Month 18, n=1318, 1350, 1328212526
Month 21, n=1281, 1326, 1287182114
Month 24, n=1263, 1293, 1244101921
Month 27, n=1233, 1262, 1206151114
Month 30, n=1222, 1221, 11667810
Month 33, n=1202, 1199, 11284510
Month 36, n=1187, 1174, 1095547
Month 39, n=1160, 1144, 105561319
Month 42, n=1149, 1126, 10354812
Month 45, n=1129, 1110, 1009356
Month 48, n=1113, 1093, 990165
SecondaryNumber of Unscheduled Visits to GP/Urologist (Outpatient) Planned, Not Relating to the Study (Including Visits Resulting From UTI, UI, Macroscopic Haematuria, Etc.)

At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with unplanned visits to GP/Urologist. Responses to the following question were recorded: "Does the participant have any unscheduled GP/Urologist (outpatients) visits planned, not relating to the study (this can include visits resulting from UTI, UI, macroscopic haematuria, etc.?". If the answer to the question was "yes," the number of visits was recorded.

Time frame:
Every 3 months from Month 3 to Month 48
Reported as:
Number · visits
Number of Unscheduled Visits to GP/Urologist (Outpatient) Planned, Not Relating to the Study (Including Visits Resulting From UTI, UI, Macroscopic Haematuria, Etc.)
visitsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Month 3, n=1550, 1581, 1564272730
Month 6, n=1479, 1516, 1514232933
Month 9, n=1439, 1465, 1477122726
Month 12, n=1400, 1431, 1434302829
Month 15, n=1343, 1386, 1381192832
Month 18, n=1318, 1350, 1328232134
Month 21, n=1281, 1326, 1287202726
Month 24, n=1263, 1293, 1244292326
Month 27, n=1233, 1262, 1206131216
Month 30, n=1222, 1221, 1166101610
Month 33, n=1202, 1199, 112861320
Month 36, n=1187, 1174, 109581218
Month 39, n=1160, 1144, 1055121018
Month 42, n=1149, 1126, 103515915
Month 45, n=1129, 1110, 1009578
Month 48, n=1113, 1093, 990748
SecondaryAdjusted Mean Change From Baseline in BPH Impact Index (BII) at Months 12, 24, 36, and 48

The BII is a 4-item questionnaire, score range of 0 (best) to 12 (worst) for questions 1-3, and 0 (best) to 13 (worst) for question 4, that assesses the overall impact of BPH on a participant's general sense of well being and measures aspects of physical discomfort, worry, and bother, all of which can be affected by BPH and its symptoms. BII score = sum of questions 1-4. Change from baseline = Post-Baseline Value. Estimates are based on the adjusted (least squares) means from the general linear model: change from baseline BII = treatment + cluster + baseline BII.

Time frame:
Baseline and Months 12, 24, 36, and 48
Reported as:
Least squares mean · points on a scale
Adjusted Mean Change From Baseline in BPH Impact Index (BII) at Months 12, 24, 36, and 48
points on a scaleDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Month 12-1.9 ± 0.06-1.5 ± 0.06-1.6 ± 0.06
Month 24-2.1 ± 0.07-1.7 ± 0.07-1.5 ± 0.07
Month 36-2.2 ± 0.07-1.8 ± 0.07-1.3 ± 0.07
Month 48-2.2 ± 0.07-1.8 ± 0.07-1.2 ± 0.07
SecondaryAdjusted Mean Change From Baseline in BPH-Related Health Status (BHS) at Months 12, 24, 36, and 48

The effect of study treatment on BHS was assessed by using three self-administered questionnaires: the International Prostate Symptom Score (IPSS), the BPH Impact Index (BII), and Patient Perception of Study Medication (PPSM). The BHS score was collected on the IPPS questionnaire and ranged from 0 (best) to 6 (worst). Percent change from baseline = \[(post-baseline - baseline)/baseline value\] x 100. Estimates were based on the adjusted (least squares) means from the general linear model: change from baseline BPH-related health status = treatment + cluster + baseline BPH-Related health status.

Time frame:
Baseline and Months 12, 24, 36, 48
Reported as:
Least squares mean · points on a scale
Adjusted Mean Change From Baseline in BPH-Related Health Status (BHS) at Months 12, 24, 36, and 48
points on a scaleDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Month 12-1.2 ± 0.03-1.0 ± 0.03-1.0 ± 0.03
Month 24-1.4 ± 0.03-1.1 ± 0.03-1.1 ± 0.03
Month 36-1.5 ± 0.03-1.2 ± 0.03-1.1 ± 0.03
Month 48-1.5 ± 0.03-1.3 ± 0.03-1.1 ± 0.03
SecondaryPatient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 1 (LOCF)

This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Since you began taking the study medication, how has control of your urinary problems changed?".

Time frame:
Baseline and Months 12, 24, 36, and 48
Reported as:
Number · participants
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 1 (LOCF)
participantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Baseline (BL), Any Improvement, n=1585, 1600, 1586696656706
BL, No Change/Any Worsening, n=1585, 1600, 1586889944880
Month (M) 12, Any Improvement, n=1576, 1593, 1581128111711218
M12, No Change/Any Worsening, n=1576, 1593, 1581295422363
M24, Any Improvement, n=1576, 1593, 1581127312001195
M24, No Change/Any Worsening, n=1576, 1593, 1581303393386
M36, Any Improvement, n=1576, 1593, 1581126812031152
M36, No Change/Any Worsening, n=1576, 1593, 1581308390429
M48, Any Improvement, n=1576, 1593, 1581127812121138
M48, No Change/Any Worsening, n=1576, 1593, 1581298381443
SecondaryPatient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 2 (LOCF)

This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "How satisfied are you with the effect of the study medication on control of your urinary problems?" Satisfact., satisfaction.

Time frame:
Baseline and Months 12, 24, 36, and 48
Reported as:
Number · participants
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 2 (LOCF)
participantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Baseline (BL), Any Satisfact., n=1587, 1600, 1583707652686
BL, Neutral/Any Dissatisfact., n=1587, 1600, 1583880948897
Month (M) 12, Any Satisfact., n=1576, 1593, 1581122411271178
M12, Neutral/Any Dissatisfact., n=1576, 1593, 1581352466403
M24, Any Satisfact., n=1576, 1593, 1581126111661150
M24, Neutral/Any Dissatisfact., n=1576, 1593, 1581315427431
M36, Any Satisfact., n=1576, 1593, 1581126011671120
M36, Neutral/Any Dissatisfact., n=1576, 1593, 1581316426461
M48, Any Satisfact., n=1576, 1593, 1581126711721088
M48, Neutral/Any Dissatisfact., n=1576, 1593, 1581309421493
SecondaryPatient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 3 (LOCF)

This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Since you began taking the study medication, how has the strength of your urinary stream changed?".

Time frame:
Baseline and Months 12, 24, 36, and 48
Reported as:
Number · participants
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 3 (LOCF)
participantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Baseline (BL), Any Improvement, n=1585, 1601, 1585629602615
BL, No Change/Any Worsening, n=1585, 1601, 1585956999970
Month (M) 12, Any Improvement, n=1576, 1593, 158118110441105
M12, No Change/Any Worsening, n=1576, 1593, 1581395549476
M24, Any Improvement, n=1576, 1593, 1581121510701057
M24, No Change/Any Worsening, n=1576, 1593, 1581361523524
M36, Any Improvement, n=1576, 1593, 1581120610711023
M36, No Change/Any Worsening, n=1576, 1593, 1581370522558
M48, Any Improvement, n=1576, 1593, 1581120210861008
M48, No Change/Any Worsening, n=1576, 1593, 1581374507573
SecondaryPatient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 4 (LOCF)

This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "How satisfied are you with the effect of the study medication on the strength of your urinary stream?". Satisfact., satisfaction.

Time frame:
Baseline and Months 12, 24, 36, and 48
Reported as:
Number · participants
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 4 (LOCF)
participantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Baseline (BL), Any Satisfact., n=1583,1601,1582632586613
BL, Neutral/Any Dissatisfact., n=1583,1601,15829511015969
Month (M) 12, Any Satisfact., n=1576, 1593, 1581115410371097
M12, Neutral/Any Dissatisfact., n=1576, 1593, 1581422556484
M24, Any Satisfact., n=1576, 1593, 1581120310721051
M24, Neutral/Any Dissatisfact., n=1576, 1593, 1581373521530
M36, Any Satisfact., n=1576, 1593, 1581120110751039
M36, Neutral/Any Dissatisfact., n=1576, 1593, 1581375518542
M48, Any Satisfact., n=1576, 1593, 1581120810891022
M48, Neutral/Any Dissatisfact., n=1576, 1593, 1581368504559
SecondaryPatient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 5 (LOCF)

This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Since you began taking the study medication, how has your pain prior to urinating changed?".

Time frame:
Baseline and Months 12, 24, 36, and 48
Reported as:
Number · participants
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 5 (LOCF)
participantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Baseline (BL), Any Improvement, n=869, 901, 849337331332
BL, No Change/Any Worsening, n=869, 901, 849532570517
Month (M) 12, Any Improvement, n=769, 817, 771556526527
M12, No Change/Any Worsening, n=769, 817, 771213291244
M24, Any Improvement, n=720, 780, 771537526535
M24, No Change/Any Worsening, n=720, 780, 771183254236
M36, Any Improvement, n=714, 753, 748540514496
M36, No Change/Any Worsening, n=714, 753, 748174239252
M48, Any Improvement, n=709, 756, 751531510489
M48, No Change/Any Worsening, n=709, 756, 751178246262
SecondaryPatient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 6 (LOCF)

This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "How satisfied are you with the effect the study medication has on your pain prior to urinating?". Satisfact., satisfaction.

Time frame:
Baseline and Months 12, 24, 36, and 48
Reported as:
Number · participants
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 6 (LOCF)
participantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Baseline (BL), Any Satisfact., n=908, 932, 889375351351
BL, Neutral/Any Dissatisfact., n=908, 932, 889533581538
Month (M) 12, Any Satisfact., n=1022, 1088, 1019712672681
M12, Neutral/Any Dissatisfact., n=1022, 1088, 1019310416338
M24, Any Satisfact., n=1077, 1151, 1085764740708
M24, Neutral/Any Dissatisfact., n=1077, 1151, 1085313411377
M36, Any Satisfact., n=1115, 1200, 1135799785736
M36, Neutral/Any Dissatisfact., n=1115, 1200, 1135316415399
M48, Any Satisfact., n=1135, 1223, 1161810792739
M48, Neutral/Any Dissatisfact., n=1135, 1223, 1161325431422
SecondaryPatient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 7 (LOCF)

This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Since you began taking the study medication, how has your pain during urination changed?".

Time frame:
Baseline and Months 12, 24, 36, and 48
Reported as:
Number · participants
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 7 (LOCF)
participantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Baseline (BL), Any Improvement, n=852, 889, 822321314319
BL, No Change/Any Worsening, n=852, 889, 822531575503
Month (M) 12, Any Improvement, n=760, 781, 755550500529
M12, No Change/Any Worsening, n=760, 781, 755210281226
M24, Any Improvement, n=706, 760, 747532508519
M24, No Change/Any Worsening, n=706, 760, 747174252228
M36, Any Improvement, n=704, 741, 733529504491
M36, No Change/Any Worsening, n=704, 741, 733175237242
M48, No Change/Any Worsening, n=702, 739, 740175252257
M48, Any Improvement, n=702, 739, 740527487483
SecondaryPatient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 8 (LOCF)

This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "How satisfied are you with the effect the study medication has on your pain during urination?". Satisfact., satisfaction.

Time frame:
Baseline and Months 12, 24, 36, and 48
Reported as:
Number · participants
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 8 (LOCF)
participantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Baseline (BL), Any Satisfact., n=890, 925, 851354348333
BL, Neutral/Any Dissatisfact., n=890, 925, 851536577518
Month (M) 12, Any Satisfact., n=1022, 1088, 1011712655678
M12, Neutral/Any Dissatisfact., n=1022, 1088, 1011310433333
M24, Any Satisfact., n=1077, 1155, 1079763730708
M24, Neutral/Any Dissatisfact., n=1077, 1155, 1079314425371
M36, Any Satisfact., n=1121, 1206, 1131807784724
M36, Neutral/Any Dissatisfact., n=1121, 1206, 1131314422407
M48, Any Satsifact., n=1146,1224,1160827785729
M48, Neutral/Any Dissatisfact., n=1146, 1224, 1160319439431
SecondaryPatient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 9 (LOCF)

This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Since you began taking the study medication, how has the way your urinary problems interfere with your ability to go about your usual activities changed?".

Time frame:
Baseline and Months 12, 24, 36, and 48
Reported as:
Number · participants
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 9 (LOCF)
participantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Baseline (BL), Any Improvement, n=1574, 1599, 1575509481494
BL, No Change/Any Worsening, n=1574, 1599, 1575106511181081
Month (M) 12, Any Improvement, n=1575, 1593, 1580112410271084
M12, No Change/Any Worsening, n=1575, 1593, 1580451566496
M24, Any Improvement, n=1575, 1593, 1580114610531049
M24, No Change/Any Worsening, n=1575, 1593, 1580429540531
M36, Any Improvement, n=1575, 1593, 1580157515931580
M36, No Change/Any Worsening, n=1575, 1593, 1580412529553
M48, Any Improvement, n=1575, 1593, 1580114810631008
M48, No Change/Any Worsening, n=1575, 1593, 1580427530572
SecondaryPatient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 10 (LOCF)

This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "How satisfied are you with the effect the study medication has on your ability to go about your usual activities without interference from your urinary problems?". Satisfact., satisfaction.

Time frame:
Baseline and Months 12, 24, 36, and 48
Reported as:
Number · participants
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 10 (LOCF)
participantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Baseline (BL), Any Satisfact., n=1574, 1600, 1576611565584
BL, Neutral /Any Dissatisfact., n=1574, 1600, 15769631035992
Month (M) 12, Any Satisfact., n=1575, 1593, 1580117610731114
M12, Neutral/Any Dissatisfact., n=1575, 1593, 1580399520466
M24, Any Satisfact., n=1575, 1593, 1580120511161088
M24, Neutral/Any Dissatisfact., n=1575, 1593, 1580370477492
M36, Any Satisfact., n=1575, 1593, 1580121010981074
M36, Neutral/Any Dissatisfact., n=1575, 1593, 1580365495506
M48, Any Satisfact., n=1575, 1593, 1580121311231043
M48, Neutral/Any Dissatisfact., n=1575, 1593, 1580362470537
SecondaryPatient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 11 (LOCF)

This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Overall, how satisfied are you with the study medication and it's effect on your urinary problems?". Satisfact., satisfaction.

Time frame:
Baseline and Months 12, 24, 36, and 48
Reported as:
Number · participants
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 11 (LOCF)
participantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Baseline (BL), Any Satisfact., n=1573, 1598, 1574717683699
BL, Neutral/Any Dissatisfact., n=1573, 1598, 1574856915875
Month (M) 12, Any Satisfact., n=1574, 1592, 158115011591202
M12, Neutral/Any Dissatisfact., n=1574, 1592, 1581324433379
M24, Any Satisfact., n=1574, 1592, 1581127911881163
M24, Neutral/Any Dissatisfact., n=1574, 1592, 1581295404418
M36, Any Satisfact., n=1574, 1592, 1581127011881119
M36, Neutral/Any Dissatisfact., n=1574, 1592, 1581304404462
M48, Any Satifact., n=1574, 1592, 1581126211821097
M48, Neutral/Any Dissatisfact., n=1574, 1592, 1581312410484
SecondaryPatient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 12 (LOCF)

This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Would you ask your doctor for the medication you received in this study?".

Time frame:
Baseline and Months 12, 24, 36, and 48
Reported as:
Number · participants
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 12 (LOCF)
participantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mg
Baseline, Yes, n=1560, 1579, 1562587557582
Baseline, No/Not Sure, n=1560, 1579, 15629731022980
Month 12, Yes, n=1574, 1592, 1581972920970
Month 12, No/Not Sure, n=1574, 1592, 1581602671611
Month 24, Yes, n=1574, 1592, 15811027955952
Month 24, No/Not Sure, n=1574, 1592, 1581547636629
Month 36, Yes, n=1574, 1592, 15811031956915
Month 36, No/Not Sure, n=1574, 1592, 1581543636666
Month 48, Yes, n=1574, 1592, 15811003918874
Month 48, No/Not Sure, n=1574, 1592, 1581571674707

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Combination—303/1,610 (18.8%)618/1,610 (38.4%)
Dutasteride 0.5 mg—339/1,623 (20.9%)586/1,623 (36.1%)
Tamsulosin 0.4 mg—348/1,611 (21.6%)590/1,611 (36.6%)
Most frequent serious events
Showing 10 of 508
Most frequent serious events
EventCombinationDutasteride 0.5 mgTamsulosin 0.4 mg
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)21/161017/162325/1611
Myocardial infarctionCardiac disorders16/161025/162320/1611
Inguinal herniaGastrointestinal disorders4/161017/162311/1611
Coronary artery diseaseCardiac disorders14/161014/162315/1611
Angina pectorisCardiac disorders14/161014/162315/1611
Urinary retentionRenal and urinary disorders2/16106/162315/1611
Cerebrovascular accidentNervous system disorders11/161015/16238/1611
PneumoniaInfections and infestations13/161010/16236/1611
OsteoarthritisMusculoskeletal and connective tissue disorders9/161013/162311/1611
Atrial fibrillationCardiac disorders11/16107/16239/1611
Most frequent other events
Most frequent other events
EventCombinationDutasteride 0.5 mgTamsulosin 0.4 mg
Erectile dysfunctionReproductive system and breast disorders167/1610147/1623109/1611
NasopharyngitisInfections and infestations134/1610129/1623149/1611
HypertensionVascular disorders133/1610147/1623136/1611
Back painMusculoskeletal and connective tissue disorders107/161088/1623113/1611
InfluenzaInfections and infestations77/161075/162383/1611

Baseline characteristics

Age, Continuous
Age, Continuous(years)Dutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mgTotal
Mean66.0 ± 7.0566.0 ± 6.9966.2 ± 7.0066.1 ± 7.01
Gender
Gender(Participants)Dutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mgTotal
Female0000
Male1610162316114844
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Dutasteride 0.5 mg Plus Tamsulosin 0.4 mgDutasteride 0.5 mgTamsulosin 0.4 mgTotal
White1421143314054259
Black22172463
Asian107106112325
American Hispanic444855147
Unknown16191550
08

Study locations

504 sites
  • GSK Investigational Site
    Birmingham, Alabama 35209, United States
  • GSK Investigational Site
    Birmingham, Alabama 35234, United States
  • GSK Investigational Site
    Birmingham, Alabama 35242, United States
  • GSK Investigational Site
    Birmingham, Alabama 35294, United States
  • GSK Investigational Site
    Columbiana, Alabama 35051, United States
  • GSK Investigational Site
    Hoover, Alabama 35216, United States
  • GSK Investigational Site
    Anchorage, Alaska 99508, United States
  • GSK Investigational Site
    Phoenix, Arizona, Arizona 86106, United States
  • GSK Investigational Site
    Phoenix, Arizona 85032, United States
  • GSK Investigational Site
    Beverly Hills, California 90212, United States
  • GSK Investigational Site
    Concord, California 94520, United States
  • GSK Investigational Site
    Glendora, California 91741, United States
  • GSK Investigational Site
    Greenbrae, California 94904, United States
  • GSK Investigational Site
    Irvine, California 92618, United States
  • GSK Investigational Site
    La Jolla, California 92093, United States
  • GSK Investigational Site
    Laguna Woods, California 92637, United States
  • GSK Investigational Site
    Los Angelas, California 90017, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    los Angeles, California 90057, United States
  • GSK Investigational Site
    Modesto, California 95350, United States
  • GSK Investigational Site
    Sacramento, California 95821, United States
  • GSK Investigational Site
    San Diego, California 91405, United States
  • GSK Investigational Site
    San Diego, California 92103, United States
  • GSK Investigational Site
    San Diego, California 92108, United States
  • GSK Investigational Site
    Torrance, California 90506, United States
  • GSK Investigational Site
    Vista, California 92084, United States
  • GSK Investigational Site
    Aventura, Florida 33180, United States
  • GSK Investigational Site
    Bay Pines, Florida 33744, United States
  • GSK Investigational Site
    Coral Gables, Florida 33134, United States
  • GSK Investigational Site
    Daytona Beach, Florida 32114, United States
  • GSK Investigational Site
    Lake Worth, Florida 33461, United States
  • GSK Investigational Site
    Miami, Florida 33156, United States
  • GSK Investigational Site
    New Smyrna Beach, Florida 32168, United States
  • GSK Investigational Site
    Ocala, Florida 34471, United States
  • GSK Investigational Site
    Orange City, Florida 32763, United States
  • GSK Investigational Site
    Pensacola, Florida 32503, United States
  • GSK Investigational Site
    Pinecrest, Florida 33156, United States
  • GSK Investigational Site
    Spring Hill, Florida 34609, United States
  • GSK Investigational Site
    St. Augustine, Florida 32086, United States
  • GSK Investigational Site
    St. Petersburg, Florida 33702, United States
  • GSK Investigational Site
    St. Petersburg, Florida 33710, United States
  • GSK Investigational Site
    Stuart, Florida 34996, United States
  • GSK Investigational Site
    Tallahassee, Florida 32308, United States
  • GSK Investigational Site
    Wellington, Florida 33414, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33407, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Blue Ridge, Georgia 30513, United States
  • GSK Investigational Site
    Calhoun, Georgia 30701, United States
  • GSK Investigational Site
    Decatur, Georgia 30033, United States
  • GSK Investigational Site
    Marietta, Georgia 30066, United States
  • GSK Investigational Site
    Meridian, Idaho 83642, United States
  • GSK Investigational Site
    Belleville, Illinois 62220, United States
  • GSK Investigational Site
    Peoria, Illinois 61602, United States
  • GSK Investigational Site
    Peoria, Illinois 61614, United States
  • GSK Investigational Site
    Wheaton, Illinois 60187, United States
  • GSK Investigational Site
    Winfield, Illinois 60190, United States
  • GSK Investigational Site
    Evansville, Indiana 47714, United States
  • GSK Investigational Site
    Jeffersonville, Indiana 47130, United States
  • GSK Investigational Site
    Newburgh, Indiana 47630, United States
  • GSK Investigational Site
    South Bend, Indiana 46601, United States
  • GSK Investigational Site
    Des Moines, Iowa 50309, United States
  • GSK Investigational Site
    Wichita, Kansas 67207, United States
  • GSK Investigational Site
    Murray, Kentucky 42071, United States
  • GSK Investigational Site
    Bossier City, Louisiana 71111, United States
  • GSK Investigational Site
    Laurel, Maryland 20724, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55417, United States
  • GSK Investigational Site
    Picayune, Mississippi 39466, United States
  • GSK Investigational Site
    Kansas City, Missouri 64114, United States
  • GSK Investigational Site
    Missoula, Montana 59802, United States
  • GSK Investigational Site
    Omaha, Nebraska 68102, United States
  • GSK Investigational Site
    Henderson, Nevada 89014, United States
  • GSK Investigational Site
    Hillsborough, New Jersey 08844, United States
  • GSK Investigational Site
    Perth Amboy, New Jersey 08861, United States
  • GSK Investigational Site
    Somerville, New Jersey 08876, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87108, United States
  • GSK Investigational Site
    Bayshore, New York 11706, United States
  • GSK Investigational Site
    Garden City, New York 11530, United States
  • GSK Investigational Site
    Great Neck, New York 11021, United States
  • GSK Investigational Site
    Lewiston, New York 14092, United States
  • GSK Investigational Site
    Asheboro, North Carolina 27203, United States
  • GSK Investigational Site
    Cary, North Carolina 27511, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28262, United States
  • GSK Investigational Site
    Durham, North Carolina 27710, United States
  • GSK Investigational Site
    Fayetteville, North Carolina 28304, United States
  • GSK Investigational Site
    Greensboro, North Carolina 27403, United States
  • GSK Investigational Site
    Salisbury, North Carolina 28144, United States
  • GSK Investigational Site
    Bismarck, North Dakota 58501, United States
  • GSK Investigational Site
    Bellbrook, Ohio 45305, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45249, United States
  • GSK Investigational Site
    Columbus, Ohio 43212, United States
  • GSK Investigational Site
    Columbus, Ohio 43214, United States
  • GSK Investigational Site
    Portland, Oregon 97239, United States
  • GSK Investigational Site
    Fleetwood, Pennsylvania 19522, United States
  • GSK Investigational Site
    Providence, Rhode Island 02904, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    Athes, Texas 75751, United States
  • GSK Investigational Site
    Dallas, Texas 75230, United States
  • GSK Investigational Site
    Dallas, Texas 75234, United States
  • GSK Investigational Site
    Dallas, Texas 75390, United States
  • GSK Investigational Site
    Fort Worth, Texas 76107, United States

Showing the first 100 of 504 sites across 36 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Antonanzas F, Brenes F, Molero JM, Fernandez-Pro A, Huerta A, Palencia R, Cozar JM. [Cost-effectiveness of the combination therapy of dutasteride and tamsulosin in the treatment of benign prostatic hyperlasia in Spain]. Actas Urol Esp. 2011 Feb;35(2):65-71. doi: 10.1016/j.acuro.2010.11.008. Epub 2011 Jan 26. Spanish. PubMed 21269736 ↗
  • Barkin J, Roehrborn CG, Siami P, Haillot O, Morrill B, Black L, Montorsi F; CombAT Study Group. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int. 2009 Apr;103(7):919-26. doi: 10.1111/j.1464-410X.2009.08196.x. Epub 2009 Feb 23. PubMed 19239460 ↗
  • Bjerklund Johansen TE, Baker TM, Black LK. Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial. BJU Int. 2012 Mar;109(5):731-8. doi: 10.1111/j.1464-410X.2011.10511.x. Epub 2011 Sep 20. PubMed 21933326 ↗
  • Black L, Grove A, Morrill B. The psychometric validation of a US English satisfaction measure for patients with benign prostatic hyperplasia and lower urinary tract symptoms. Health Qual Life Outcomes. 2009 Jun 19;7:55. doi: 10.1186/1477-7525-7-55. PubMed 19545384 ↗
  • Chung BH, Roehrborn CG, Siami P, Major-Walker K, Morrill BB, Wilson TH, Montorsi F. Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH. Prostate Cancer Prostatic Dis. 2009;12(2):152-9. doi: 10.1038/pcan.2008.49. Epub 2008 Sep 23. PubMed 18813219 ↗
  • Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F; CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010 Jan;57(1):123-31. doi: 10.1016/j.eururo.2009.09.035. Epub 2009 Sep 19. Erratum In: Eur Urol. 2010 Nov;58(5):801. PubMed 19825505 ↗
  • Roehrborn CG, Andriole GL, Wilson TH, Castro R, Rittmaster RS. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial. Eur Urol. 2011 Feb;59(2):244-9. doi: 10.1016/j.eururo.2010.10.040. Epub 2010 Nov 4. PubMed 21093145 ↗
  • Roehrborn CG, Barkin J, Siami P, Tubaro A, Wilson TH, Morrill BB, Gagnier RP. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial. BJU Int. 2011 Mar;107(6):946-54. doi: 10.1111/j.1464-410X.2011.10124.x. Epub 2011 Feb 18. PubMed 21332630 ↗
  • Roehrborn CG, Wilson TH, Black LK. Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial. J Urol. 2012 May;187(5):1732-8. doi: 10.1016/j.juro.2011.12.083. Epub 2012 Mar 15. PubMed 22425127 ↗
  • Becher E, Roehrborn CG, Siami P, Gagnier RP, Wilson TH, Montorsi F. The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study. Prostate Cancer Prostatic Dis. 2009;12(4):369-74. doi: 10.1038/pcan.2009.37. Epub 2009 Sep 1. PubMed 19901936 ↗
  • Montorsi F, Roehrborn C, Garcia-Penit J, Borre M, Roeleveld TA, Alimi JC, Gagnier P, Wilson TH. The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study. BJU Int. 2011 May;107(9):1426-31. doi: 10.1111/j.1464-410X.2011.10129.x. Epub 2011 Feb 23. PubMed 21348912 ↗
  • Montorsi F, Henkel T, Geboers A, Mirone V, Arrosagaray P, Morrill B, Black L. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study. Int J Clin Pract. 2010 Jul;64(8):1042-51. doi: 10.1111/j.1742-1241.2010.02428.x. Epub 2010 May 7. PubMed 20487046 ↗
  • Haillot O, Fraga A, Maciukiewicz P, Pushkar D, Tammela T, Hofner K, Chantada V, Gagnier P, Morrill B. The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study. Prostate Cancer Prostatic Dis. 2011 Dec;14(4):302-6. doi: 10.1038/pcan.2011.13. Epub 2011 Apr 19. PubMed 21502969 ↗
  • Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Morrill B, Montorsi F; CombAT Study Group. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008 Feb;179(2):616-21; discussion 621. doi: 10.1016/j.juro.2007.09.084. Epub 2007 Dec 21. Erratum In: J Urol. 2008 Sep;180(3):1191. PubMed 18082216 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2003, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2010, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2004
First posted
Aug 26, 2004
Start
Nov 2003
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Results first posted
Mar 16, 2010
Last update
Feb 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00090103
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 26, 2004
Start date
Nov 2003
Primary completion
Apr 2009
Completion
Apr 2009
Results posted
Mar 16, 2010
Last update
Feb 28, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dutasteride · Tamsulosin

Start the discussion